Newborn Screening Market To Reach $1,797.38 Million By 2033

Newborn Screening Market Growth & Trends

The global newborn screening market size is expected to reach USD 1,797.38 million by 2033, registering a CAGR of 8.1% from 2025 to 2033, according to a new report by Grand View Research, Inc. The growth of the market for newborn screening is majorly attributed to favorable reimbursement policies and government support programs, as well as the presence of key players focusing on developing efficient screening tests. In addition, high birth rates in the most populous economies such as China and India, coupled with high disposable income, are factors anticipated to drive the market positively.

According to Indian Paediatrics Report 2022, NBS has become a staple in public health prevention, and its panel is always growing. Specific DBS-based metabolic testing tools continue to be crucial in NBS. Genetic and genomic testing have become effective tools because of scientific advancements. Both, however, have advantages and drawbacks. The present NBS efficiency for some genetic illnesses will be increased by the integrated analysis of metabolic and genetic data, allowing more affected people to obtain early diagnosis and treatment, which will improve their prognosis.

In addition, government programs and legislation also create a favorable environment to foster market growth. The newborn screening program was recommended by the WHO to safeguard the health of children globally. Under this program, numerous policies and initiatives have been taken by the Japan’s Society of Obstetrics and Gynecology (JSOG), U.S. Department of Health and Human Services Secretary’s Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC), UK (PEACH), and advocacy groups like the March of Dimes.

Moreover, in June 2022, Novartis entered into a strategic partnership with the American Society of Hematology to deal with sickle cell disease amongst newborns in an additional six African countries. ASH’s Consortium on Newborn Screening in Africa (CONSA) will provide early intervention and screening programs at several institutions in countries such as Ghana, Liberia, Kenya, Nigeria, Tanzania, Uganda, and Zambia.

Additionally, more focus on innovation in the field of newborn screening is expected to drive market growth. For instance, in August 2022, Trivitron Healthcare launched a Centre of Excellence for newborn screening, genomics, molecular diagnostics, and metabolomics. Cancer markers based on ELISA, PCR, and IVD CE-approved kits for newborn screening will be manufactured at the facility.

 Request a free sample copy or view report summary: Newborn Screening Market Report

Newborn Screening Market Report Highlights

• The instrument segment held the largest share of 76.09% of the newborn screening market in 2024, owing to the growing number of newborn screening procedures, increasing investments, and rising awareness about early disease detection, which are estimated to drive the instrument segment during the forecast period.

• Tandem mass spectrometry dominated the newborn screening market in 2024, with a 24.77% share due to its cost-effectiveness, increased application, and technological advancements.

• Dry blood spot tests dominated the newborn screening market, accounting for over 46.01% of revenue in 2024, and are expected to grow at the fastest CAGR over the forecast period.

• Asia Pacific newborn screening market accounted for the largest share of 33.30% in 2024, due to improving infrastructure and healthcare plans and the availability of new opportunities for expansion are expected to play a major role in driving demand over the forecast period

Newborn Screening Market Segmentation

Grand View Research has segmented the newborn screening market based on product, technology, test type, and region:

Newborn Screening Product Outlook (Revenue, USD Million, 2021 - 2033)

• Instruments

• Reagents

Newborn Screening Technology Outlook (Revenue, USD Million, 2021 - 2033)

• Tandem mass spectrometry

• Pulse oximetry

• Enzyme based assay

• DNA assay

• Electrophoresis

• Others

Newborn Screening Test Type Outlook (Revenue, USD Million, 2021 - 2033)

• Dry blood spot test

• CCHD

• Hearing screen

Newborn Screening Regional Outlook (Revenue, USD Million, 2021 - 2033)

• North America

  • U.S.

  • Canada

  • Mexico

• Europe

  • Germany

  • UK

  • France

  • Italy

  • Spain

  • Denmark

  • Sweden

  • Norway

• Asia Pacific

  • Japan

  • China

  • India

  • Australia

  • South Korea

  • Thailand

  • South Korea

• Latin America

  • Brazil

  • Argentina

• Middle East and Africa (MEA)

  • South Africa

  • Saudi Arabia

  • UAE

  • Kuwait

List of Key Players in Newborn Screening Market

• Bio-Rad Laboratories

• Agilent Technologies

• Masimo

• Waters Corporation

• Natus Medical

• Trivitron Healthcare

• GE Lifesciences

• PerkinElmer Inc

• AB SCIEX

• Demand A/S

• Parseq LAB

• Otodynamics

• Zentech

• Centogene